Intraday Trading Solution👍

223🔥

220🔥

218🔥

216🔥

✅INTRADAY+SWING ✅ BUY PERSISTENT JUL 6300CE AROUND 195-215 TRG 220/230/240 wait for activation near Entry price

⚠️ Market Notes • Global Sentiment: Positive (Middle East de-escalation) • India VIX: Volatility easing • FII/DII Flows: FIIs were net sellers; DIIs supported markets • Action Point: Trade with strict stop-losses and confirmation above/below breakout levels

📌 Tips for Today • Use tight stop-losses near pivot levels • Avoid trades near mid-range—wait for breakouts • Monitor global news & institutional flows • Don’t chase trades—wait for clear confirmation

🟢 SENSEX – Intraday Levels & Strategy • Resistance Levels: 82,600 → 82,850 • Support Levels: 82,200 → 81,900 • Strategy: ✅ Buy above 82,600 (target: 82,850) ❌ Sell below 82,200 (target: 81,900) • Trend Note: Overall structure is positive, tracking Nifty. Watch for sustained move above 82,600 for fresh upside.

🟡 BANK NIFTY – Intraday Levels & Strategy • Resistance Levels: 56,790 → 57,120 • Support Levels: 56,400 → 56,200 → 55,950 • Strategy: ✅ Buy above 56,610 (target: 56,800–57,120) ❌ Sell below 56,400 (target: 56,200 / 55,950) • Momentum Note: Bias remains positive above 56,550. Below 56,400, weakness may build up.

🔵 NIFTY 50 – Intraday Levels & Strategy • Resistance Levels: 25,160 → 25,200 → 25,350 • Support Levels: 25,025 → 24,900 • Strategy: ✅ Buy above 25,160 (target: 25,350+ with SL below 25,025) ❌ Sell below 25,025 (target: 24,900 with SL above 25,100) • Technical Note: Trading within rising channel; neutral RSI, so breakout above 25,200 is key.

STOCKS IN THE WATCH J.B. Chemicals & Pharmaceuticals: The company has received approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA), Amitriptyline Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg, which is indicated for relief of symptoms of depression. Aurobindo Pharma: In its filing to stock exchanges, CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Ltd, has obtained marketing authorisation from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for Dyrupeg™, its pegylated filgrastim biosimilar version. Earlier in April 2025, Dyrupeg™ received marketing authorisation in the European Union from the European Commission (EC). This is CuraTeQ’s third biosimilar to be approved by MHRA after the approval of Bevqolva™ in December 2024 and Zefylti™ in May 2025. HDFC Bank: Shares will be in focus as arm HDB Financial Services will launch its IPO today. The NBFC aims to raise ₹12,500 crore from the public issue. Timex Group India: Shares will be in focus as Timex Group Luxury Watches BV, the global watchmaker, will sell a 15% share in its Indian entity, Timex Group India, through an offer for sale (OFS). The OFS is scheduled to open for non-retail investors on Wednesday, June 25, Mastek: The company said that Raghavendra Jha, Chief Financial Officer and Key Managerial Personnel of the company, has submitted his resignation from the services of the company through email on June 23, 2025. Bajel Projects: In its press release, the company said it has secured an order from a leading private player in the energy and power transmission sector. This order falls within the "Large" order band (valued between ₹100 crore and ₹200 crore), as per the company's internal classification. RITES: The company has received the Letter of Intent from Gujarat Urban Development Company Limited for “Appointment of TPI agency for WSS/UGD/STP projects under Amrut 2.0/SJMMSVY under GUDC for ULBs of Gujarat”. The size of the order is ₹28.50 crore, exclusive of GST. Glenmark Pharma: The pharma company has launched TEVIMBRA® (tislelizumab) in India following the approval by the Central Drugs Standard Control Organisation (CDSCO). TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines), a global oncology leader committed to delivering advanced treatments for cancer patients worldwide. Hindalco: Aditya Birla Group's metals arm Hindalco Industries Ltd on Tuesday said it will acquire US-based AluChem Companies Inc. for $125 million (₹1,075 crore) in an all-cash deal.

Good morning guys 😊